Dopamine and Parkinson's disease. a personal view of the past, the present, and the future
Hornykiewicz, O.
Advances in Neurology 86: 1-11
2001
ISSN/ISBN: 0091-3952 PMID: 11553966 Document Number: 530189
Document emailed within 1 workday
Related Documents
Garcia, A. 2005: Dental magnification: a clear view of the present and a close-up view of the future Compendium of Continuing Education in Dentistry 26(6a Suppl): 459-463Cridland, J.S. 1984: The future of analytical pharmacology--a personal view South African Medical Journal 65(5): 172-173
Warwick, R. 1978: The future of Nomina Anatomica. A personal view Minerva Medica 69(7): 461-463
Gekht, A.B. 2002: Use of dopamine agonists in the treatment of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 102(9): 54-58
Molho, E.S.; Factor, S.A.; Weiner, W.J.; Sanchez-Ramos, J.R.; Singer, C.; Shulman, L.; Brown, D.; Sheldon, C. 1995: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease Journal of Neural Transmission. Supplementum 45: 225-230
Stoessl, A.J.; de la Fuente-Fernández, R.úl. 2003: Dopamine receptors in Parkinson's disease: imaging studies Advances in Neurology 91: 65-71
Kish, S.; Rajput, A.; Gilbert, J.; Rozdilsky, B.; Chang, L.J.; Shannak, K.; Hornykiewicz, O. 1987: GABA-dopamine relationship in Parkinson's disease striatum Advances in Neurology 45: 75-77
Jenner, P. 2005: A novel dopamine agonist for the transdermal treatment of Parkinson's disease Neurology 65(2 Suppl 1): S3-S5
Olanow, C.Warren. 2002: The role of dopamine agonists in the treatment of early Parkinson's disease Neurology 58(4 Suppl 1): S33-S41
Sweet, R.D.; Wasterlain, C.; McDowell, F.H. 1974: Piribedil--an oral dopamine agonist for treatment of Parkinson's disease Transactions of the American Neurological Association 99: 258-260
Gerfen, C.R. 2000: Dopamine-mediated gene regulation in models of Parkinson's disease Annals of Neurology 47(4 Suppl 1): S42
Löschmann, P.A.; Kunow, M.; Wachtel, H. 1992: Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease Journal of Neural Transmission. Supplementum 38: 55-64
2002: Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved MMW Fortschritte der Medizin Suppl. 2: 88
Figuerido, J.A.; De la Herrán, J. 1970: Personal experience in the treatment of Parkinson's disease with L-Dopa Revista Clinica Espanola 119(6): 555-562
Bode, M. 2009: Dopamine agonist therapy in early Parkinson's disease. a survey of a Cochrane review Ugeskrift for Laeger 171(41): 2996-2999
Szczudlik, A.; Rudzińska, M. 2007: Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes Neurologia i Neurochirurgia Polska 41(2 Suppl 1: S6-S9
Streifler, M.; Vardi, Y.; Kesten, M.; Oberman, Z.; Herzberg, M. 1972: Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease Israel Journal of Medical Sciences 81(5): 597-601
Albin, R.L.; Nichols, T.E.; Frey, K.A. 2002: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288(3): 311
Ahlskog, J.Eric.; Maraganore, D.M.; Uitti, R.J.; Uhl, G.R. 2002: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288(3): 311; Author Reply 312-3
Buscaino, G.A.; Sori, A.; Campanella, G. 1972: Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa Revue Neurologique (Paris) 127(2): 301-302